Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.
The effects of somatostatin on tolbutamide-stimulated insulin release were studied in 4 patients with insulin-producing tumors of the pancreas and in 6 normal subjects.  In contrast to its effective inhibition of insulin release in normal subjects, somatostatin, without exception, failed to inhibit tolbutamide-induced insulin release in the patients with pancreatic beta-cell tumors.  This differential effect of somatostatin may prove useful in the diagnosis of insulin-producing tumors of the pancreas.
D007516:Adenoma, Islet Cell / Q000378:metabolism*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013004:Somatostatin; D013997:Time Factors; D014044:Tolbutamide
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D014044:Tolbutamide